Mizuho raised the firm’s price target on Verastem (VSTM) to $9 from $7 and keeps an Outperform rating on the shares. The firm updateed its model to reflect the prospects of Verastem’s lead asset avutometinib plus defactinib in low grade serous ovarian cancer. The next data catalyst is coming soon, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Verastem announces preliminary avutometinib and sotorasib data
- Verastem Inc. Reports Increased Operating Expenses and Net Loss
- Verastem price target lowered to $14 from $20 at Alliance Global Partners
- Verastem cuts FY24 EPS view to $4.17-$4.23 from $4.25-$4.35, consensus $4.28
- Verastem reports Q3 EPS (60c), consensus (74c)